| 1. |
- Fenske, Markus, et al.
(författare)
-
Improved Electrical Performance of Perovskite Photovoltaic Mini-Modules through Controlled PbI2 Formation Using Nanosecond Laser Pulses for P3 Patterning
- 2021
-
Ingår i: Energy Technology. - : Wiley. - 2194-4288 .- 2194-4296. ; 9:4
-
Tidskriftsartikel (refereegranskat)abstract
- The upscaling of perovskite solar cells to modules requires the patterning of the layer stack in individual cells that are monolithically interconnected in series. This interconnection scheme is composed of three lines, P1–P3, which are scribed using a pulsed laser beam. The P3 scribe is intended to isolate the back contact layer of neighboring cells, but is often affected by undesired effects such as back contact delamination, flaking, and poor electrical isolation. Herein, the influence of the laser pulse duration on the electrical and compositional properties of P3 scribe lines is investigated. The results show that both nanosecond and picosecond laser pulses are suitable for P3 patterning, with the nanosecond pulses leading to a higher open circuit voltage, a higher fill factor, and a higher power conversion efficiency. It is found that the longer pulse duration resultes in a larger amount of PbI2 formed within the P3 line and a thin Br-rich interfacial layer which both effectively passivate defects at the scribe line edges and block charge carrier in its vicinity. Thus, nanosecond laser pulses are preferable for P3 patterning as they promote the formation of beneficial chemical phases, resulting in an improved photovoltaic performance.
|
|
| 2. |
- Gerbitz, Armin, et al.
(författare)
-
Prevention of CMV/EBV reactivation by double-specific T cells in patients after allogeneic stem cell transplantation : results from the randomized phase I/IIa MULTIVIR-01 study
- 2023
-
Ingår i: Frontiers in Immunology. - : Frontiers Media S.A.. - 1664-3224. ; 14
-
Tidskriftsartikel (refereegranskat)abstract
- IntroductionAllogeneic stem cell transplantation is used to cure hematologic malignancies or deficiencies of the hematopoietic system. It is associated with severe immunodeficiency of the host early after transplant and therefore early reactivation of latent herpesviruses such as CMV and EBV within the first 100 days are frequent. Small studies and case series indicated that application of herpes virus specific T cells can control and prevent disease in this patient population.MethodsWe report the results of a randomized controlled multi centre phase I/IIa study (MULTIVIR-01) using a newly developed T cell product with specificity for CMV and EBV derived from the allogeneic stem cell grafts used for transplantation. The study aimed at prevention and preemptive treatment of both viruses in patients after allogeneic stem cell transplantation targeting first infusion on day +30. Primary endpoints were acute transfusion reaction and acute-graft versus-host-disease after infusion of activated T cells.ResultsThirty-three patients were screened and 9 patients were treated with a total of 25 doses of the T cell product. We show that central manufacturing can be achieved successfully under study conditions and the product can be applied without major side effects. Overall survival, transplant related mortality, cumulative incidence of graft versus host disease and number of severe adverse events were not different between treatment and control groups. Expansion of CMV/EBV specific T cells was observed in a fraction of patients, but overall there was no difference in virus reactivation.DiscussionOur study results indicate peptide stimulated epitope specific T cells derived from stem cell grafts can be administered safely for prevention and preemptive treatment of reactivation without evidence for induction of acute graft versus host disease.Clinical trial registrationhttps://clinicaltrials.gov, identifier NCT02227641.
|
|
